Skip to main content

What the FDA labels say about taking them together

Cobicistat and disopyramide

Cobicistat's FDA label of February 10, 2026 names disopyramide in its drug interactions section; the disopyramide label PlainMeds reads does not name cobicistat. The cobicistat label: “Clinical monitoring is recommended upon coadministration with antiarrhythmics.”

Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the cobicistat label say about disopyramide?

Cobicistat label, drug interactions

Concomitant Drug Class/Drug Name: Other antiarrhythmics: e.g., amiodarone disopyramide flecainide mexiletine propafenone quinidine; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ antiarrhythmics; Clinical Comment: Clinical monitoring is recommended upon coadministration with antiarrhythmics.

Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed

What does the disopyramide label say about cobicistat?

Disopyramide's label (effective August 24, 2026) does not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Cobicistat generic labelers
2Disopyramide generic labelers
CobicistatDisopyramide
Labeled forHIVn/a
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.801 per capsule 100 mg capsule
Shortage nowA presentation being discontinuedA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?